Management of angina

Current situation  

Angina is a very common problem. In the UK more than two million people are affected by the condition.   

Thirty per cent of patients with recent-onset angina will suffer a major cardiac event such as death, MI or revascularisation within two years.  

What is the evidence?  

Most of the existing evidence would suggest that a beta-blocker is the first-line prophylactic agent when regular symptom control of angina is required (unless contraindicated).   

Management options for patients with refractory angina include procedures which are still being evaluated in trials, for example spinal cord stimulation and transmural myocardial laser revascularisation (Curr Cardiol Rep 2006; 8: 272). 

Ivabradine is the first selective sinus node If inhibitor. It reduces heart rate while maintaining myocardial contractility and atrioventricular conduction. It has been shown to be as effective as atenolol in patients with stable angina (Eur Heart J 2005; 26: 2,529).  

Women with angina often present differently to men. Cardiac investigations such as ECG and exercise tolerance tests are actually less specific and less sensitive in women (BMJ 2005; 331: 467).  

Analysis of the IONA trial has shown that adding nicorandil to existing antianginal treatment is cost-effective for patients because it leads to lower incidence of cardiovascular disease (CVD) (Heart 2006; 92: 619).  

Implications for practice  

There are still wide variations in the quality of care.  There is some evidence that gaps remain between best practice and usual care in the management of stable angina (Eur Heart J 2005; 26: 996).   

One study showed that only 40 per cent of those people taking lipid-lowering treatment actually had cholesterol levels below target. Only about half of those at high risk of CVD were treated with a statin (Circulation 2006; 113: 647).  

Most GPs now have access to chest pain clinics.   

Available guidelines  

The SIGN guidelines recommend that all patients with recent-onset angina should be considered for review by a cardiologist.   

The NSF for CHD states that people with angina should be offered investigation and treatment to relieve their pain and also to reduce the risk of coronary events (NSF for CHD. DoH. London: 2000).  

Although current guidelines do not include ACE inhibitors, many clinicians prescribe ACE inhibitors for patients with angina.  

Useful websites  

www.bcs.com — British Cardiac Society  

www.pccs.org.uk — Primary Care Cardiovascular Society  

www.bhsoc.org — British Hypertension Society  

Dr Louise Newson is a GP in the West Midlands and author of ‘Hot Topics for MRCGP and General Practitioners’, Pas Test 2006  

Key points  

CHD is the most common cause of death in the UK.

ACE inhibitors are increasingly being used.  

Many patients are still not reaching target cholesterol levels.  

New treatments for angina are emerging. 

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

NHS operating procedure for primary care to remain until UK lifts all COVID-19 restrictions

NHS operating procedure for primary care to remain until UK lifts all COVID-19 restrictions

The NHS standard operating procedure (SOP) for primary care will remain in place...

All adults in England to book COVID jab 'this week' as UK hits 30m second doses

All adults in England to book COVID jab 'this week' as UK hits 30m second doses

All adults should be able to book their first COVID-19 jab by the ‘end of this week’...

NHS faces workforce 'pinch point' as COVID-19 drives wave of retirements, warns GMC

NHS faces workforce 'pinch point' as COVID-19 drives wave of retirements, warns GMC

Numbers of doctors working in the NHS will soon reach a ‘pinch point’ unless immediate...

UK COVID-19 vaccination programme tracker

UK COVID-19 vaccination programme tracker

GPs across the UK are playing a leading role in the largest-ever NHS vaccination...

NHS England pledges £30m for GPs to boost long COVID diagnosis and care

NHS England pledges £30m for GPs to boost long COVID diagnosis and care

NHS England has promised £30m for general practice to improve diagnosis and care...

Second dose COVID jabs for over-40s to be accelerated as lifting restrictions is delayed

Second dose COVID jabs for over-40s to be accelerated as lifting restrictions is delayed

Second doses of COVID-19 vaccines in England will be 'accelerated' for all over-40s...